In today’s briefing:
- Limited Upside To JBM (2161 HK)’s Spin-Off
- JBM (Healthcare) (2161 HK): Synthetic Expert Call Transcript (21 Jul 2026)
- ImmVira (亦诺微) Pre-IPO: Prospectus Update Suggests Stronger Bladder Data but a Higher Competitive Bar
- Bumrungrad Versus Bangkok Dusit Medical: Will the Divergent Trend Continue?
- HITI: High Tide hosts an informative Q&A session on a prominent social media platform that provided important updates on the overall business.
- Upgrading Communications (XLC) To Market Weight; A.I. Names to Remain Under Pressure?
Limited Upside To JBM (2161 HK)’s Spin-Off
- On the 17th July 2026 , JBM (Healthcare) (2161 HK), a consumer healthcare company, announced the spin-off of 100%-held JPJ, the group’s branded PCM products and Chinese medicine clinic services.
- Listing is slated for the HKEx, market conditions permitting. An application proof has been lodged. JBM intends to hold at least 50% of JPJ post listing.
- My calcs suggest JBM is fairly valued here – before assigning any holdco discount post spin-off. FWIW, JBM was itself spun-off from Jacobson Pharma (2633 HK) in February 2021.
JBM (Healthcare) (2161 HK): Synthetic Expert Call Transcript (21 Jul 2026)
- The Proposed Spin-Off of JPJ (TCM) Limited Lacks Commercial Substance: Creating a three-tier listed structure (Jacobson Pharma to JBM Healthcare to JPJ) serves as financial engineering rather than operating synergy. It will exacerbate holding company discounts across the group and severely restrict JBM’s post-transaction equity liquidity, leaving JBM as an hollowed-out holding company.
- Clinic Acquisitions Dilute JPJ’s High-Margin Heritage Profile: JPJ’s historical strength lies in its dominant 9.2% market share in the Hong Kong Proprietary Chinese Medicine (PCM) space, backed by high-margin legacy brands like Po Chai Pills. However, its recent downstream expansion into lower-margin, labor-and-rent-intensive clinic chains (Kenford and King Pui) compresses consolidated margins and threatens the return-on-capital profile.
- Severe Corporate Governance and Transfer Pricing Risks Exist: High ownership concentration under Derek Sum, combined with rapid connected transactions—such as selling a stake in Li Chung Shing Tong in November 2024 at HK$460 per share and buying it back in June 2026 at HK$600 per share—indicates value leakage from minority shareholders of JBM to the parent. JPJ’s massive HK$506.8 million net current liabilities as of March 31, 2026, highlights major intercompany restructuring risks.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
ImmVira (亦诺微) Pre-IPO: Prospectus Update Suggests Stronger Bladder Data but a Higher Competitive Bar
- ImmVira, a China-based clinical-stage biotech company, is seeking a Hong Kong Chapter 18A listing. Citigroup and CICC are the joint sponsors.
- In our previous note, we looked at the company’s core product MVR-T3011, including its mechanism and clinical data, as well as its management and investor backing.
- In this note, we look at developments in the company’s assets and the competitive setting.
Bumrungrad Versus Bangkok Dusit Medical: Will the Divergent Trend Continue?
- Bumrungrad Hospital (BH TB) shares advanced 27% over the last one year, while its larger peer Bangkok Dusit Medical Services (BDMS TB) shares fell 8% over the same period.
- Financial performance of these two companies justifies their respective share price movements. BH maintained its financial performance superiority to BDMS in recent times.
- Share price movement is not expected to change direction soon. BH shares are trading at EV/EBITDA of 12.6x, higher than BDMS (11.4x). Higher growth and superior profitability justify premium valuation.
HITI: High Tide hosts an informative Q&A session on a prominent social media platform that provided important updates on the overall business.
- High Tide is the largest cannabis retailer in Canada operating 228 stores across Alberta, Ontario, Saskatchewan, BC, and Manitoba.
- Beyond traditional physical cannabis stores in Canada (Canna Cabana), the company markets Cannabidiol (CBD) and consumption accessories online across Canada, U.S., U.K. and Europe.
- More recently, HITI closed the acquisition of a 51% ownership stake in Remexian Pharma GmbH, a leading low-cost medical cannabis importer and wholesaler in Germany, which is a high-growth market.
Upgrading Communications (XLC) To Market Weight; A.I. Names to Remain Under Pressure?
- We remain bullish (as of our 4/21/26 Compass) on the S&P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM).
- With that said, we have expressed our concern over the past two weeks in our reports, particularly as it relates to a prolonged consolidation for QQQ/Technology (XLK).
- We continue to believe a consolidation/continuation of the short-term downtrends is likely through mid-to-late-August amid ongoing choppy price action for semiconductors (SOXX), memory (DRAM), and optical equipment/photonics (EUV) names.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
